用于弥漫性大B细胞淋巴瘤（DLBCL）的艾可瑞妥单抗（Epkinly） - Suppr | 超能文献

Epcoritamab (Epkinly) for diffuse large B-cell lymphoma (DLBCL).

出版信息

Med Lett Drugs Ther. 2023 Jun 12;65(1678):e103-e104. doi: 10.58347/tml.2023.1678d.

DOI:10.58347/tml.2023.1678d

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Epcoritamab (Epkinly) for diffuse large B-cell lymphoma (DLBCL).用于弥漫性大B细胞淋巴瘤（DLBCL）的艾可瑞妥单抗（Epkinly）

Med Lett Drugs Ther. 2023 Jun 12;65(1678):e103-e104. doi: 10.58347/tml.2023.1678d.

2

Glofitamab (Columvi) for diffuse large B-cell lymphoma.用于弥漫性大B细胞淋巴瘤的 glofitamab（Columvi）。

Med Lett Drugs Ther. 2023 Aug 7;65(1682):e129-e130. doi: 10.58347/tml.2023.1682b.

3

[Current status and future prospects of diffuse large B-cell lymphoma treatment].[弥漫性大B细胞淋巴瘤治疗的现状与未来展望]

Rinsho Ketsueki. 2022;63(9):1126-1134. doi: 10.11406/rinketsu.63.1126.

4

Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.来那度胺联合环磷酰胺、多柔比星、长春新碱、泼尼松和利妥昔单抗治疗未经治疗的老年弥漫性大 B 细胞淋巴瘤患者安全有效：一项由意大利淋巴瘤基金会开展的 I 期研究。

Haematologica. 2013 Nov;98(11):1732-8. doi: 10.3324/haematol.2013.085134. Epub 2013 Jun 28.

5

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.来那度胺维持治疗对比安慰剂用于一线利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗的老年弥漫性大 B 细胞淋巴瘤患者。

J Clin Oncol. 2017 Aug 1;35(22):2473-2481. doi: 10.1200/JCO.2017.72.6984. Epub 2017 Apr 20.

6

Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.在预后不良的未经治疗的弥漫性大 B 细胞非霍奇金淋巴瘤的非常老年患者中，使用利妥昔单抗的剂量调整的输注环磷酰胺、多柔比星、长春新碱和泼尼松化疗的活性和安全性。

Cancer. 2011 Mar 1;117(5):964-73. doi: 10.1002/cncr.25582. Epub 2010 Oct 19.

7

Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma.特法西单抗治疗难治/复发弥漫性大 B 细胞淋巴瘤。

Drugs Today (Barc). 2021 Sep;57(9):571-580. doi: 10.1358/dot.2021.57.9.3306767.

8

Lenalidomide in DLBCL: are we past the cell of origin?来那度胺治疗弥漫性大 B 细胞淋巴瘤：我们是否超越了细胞起源？

Clin Adv Hematol Oncol. 2021 May;19(5):320-325.

9

Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study.来那度胺联合 R-CHOP 方案治疗滤泡性淋巴瘤转化的弥漫性大 B 细胞淋巴瘤新诊患者的疗效：来自 2 期 MC078E 研究的结果。

Blood Cancer J. 2021 Sep 25;11(9):160. doi: 10.1038/s41408-021-00542-z.

10

Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.具有介于经典霍奇金淋巴瘤和弥漫性大 B 细胞淋巴瘤之间特征的灰色区域淋巴瘤：大型多中心队列中的特征、结局和预后。

Am J Hematol. 2015 Sep;90(9):778-83. doi: 10.1002/ajh.24082.

引用本文的文献

1

T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors.T 细胞刺激疫苗增强了 CD3 双特异性抗体疗法在实体肿瘤中的疗效。

Nat Commun. 2024 Jan 2;15(1):48. doi: 10.1038/s41467-023-44308-6.